Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (20519)	5/11/1998 9:13:00 PM
From: Machaon	Read Replies (4) \| Respond to of 32384

<< "We believe that the net effect, following closing of the merger, transfer of ONTAK rights from Lilly to Ligand, and launch of ONTAK following regulatory approval, is significantly accretive to Ligand earnings in 1999 and beyond," he said. >> Sounds like Robinson has a lot of confidence. Does Wall Street have confidence in Robinson and LGND? Personally, I like the addition of the science to LGND's pipeline. I'd like to see an analyst update on EPS projections. I'll make a prediction for tomorrow. We'll have our normal, large rally, with almost 1 million shares traded, and close up a whopping 1/16th! ( : > { Good luck, Bob

To: squetch who wrote (20519)	5/11/1998 9:16:00 PM
From: RXGOLF	Read Replies (2) \| Respond to of 32384

Maybe I'm a worrier, but since Ligand will soon have approved drugs, and Ligand plans to soon be profitable, Ligand will need to market these drugs. What will a marketing team and sales force cost the company? Even if they use an outside marketing team, they will need their own sales force. I would think this would be very expensive to put together from the ground up. is this just a minor thing to a company in Ligands position?? Greg

To: squetch who wrote (20519)	5/11/1998 9:20:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

Squetch, I went back and re-read the earlier posting I got the numbers from and I was wrong. It said a total of 16,000 patients which matches your 500-1,000 new case in the US per year pretty well. But I'd guess that you can triple that to get a worldwide market (I'm looking only at the wealthy part of the world; the rest won't get treated no matter how good the drug is). So it could be a pretty reasonable little revenue stream. Sure, it wasn't profitable for Seragen. Part of the reason was the manufacturing facility. But Ligand could use that for other things as well.... I'll withhold judgement for a bit. I am guessing that Robinson and crew know exactly what they are doing. Don't forget that they are sure to have a lot more at stake financially than most of us.... Cheers, Torben